Phase 0 PK Study of ACD856 Microdose in Healthy Volunteers

Phase 1, open-label, single-arm trial of ACD856 in Alzheimer's disease (AD) and cognitive disorder (CD), sponsored by AlzeCure Pharma. Primary endpoints: Area under the plasma concentration vs time curve from time zero extrapolated to infinity at 24 hours, Area under the plasma concentration vs time curve from time zero to time of last quantifiable analyte concentration at 96 hours and 3 more. Started Jan 2020; status: completed.